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association study (GWAS) with HS-Aging pathology as endophenotype.  In
collaboration with the Alzheimer's Disease Genetics Consortium, data were analyzed
from large autopsy cohorts: (#1) National Alzheimer's Coordinating Center (NACC);
(#2) Rush University Religious Orders Study and Memory and Aging Project; (#3)
Group Health Research Institute Adult Changes in Thought study; (#4) University of
California at Irvine 90+ Study; and (#5) University of Kentucky Alzheimer's Disease
Center.  Altogether, 363 HS-Aging cases and 2,303 controls, all pathologically
confirmed, provided statistical power to test for risk alleles with large effect size.  A two-
tier study design included GWAS from cohorts #1-3 (Stage I) to identify promising SNP
candidates, followed by focused evaluation of particular SNPs in cohorts #4-5 (Stage
II).  Polymorphism in the ATP-binding cassette, sub-family C member 9 (ABCC9) gene,
also known as sulfonylurea receptor 2 (SUR2), was associated with HS-Aging
pathology.  In the meta-analyzed Stage I GWAS, ABCC9 polymorphisms yielded the
lowest p-values, and, factoring in the Stage II results, the meta-analyzed risk SNP
(rs704178:G) attained genome-wide statistical significance (p=1.4x10-9), with odds
ratio (OR) of 2.13 (recessive mode of inheritance).  For SNPs previously linked to
hippocampal sclerosis, meta-analyses of Stage I results show OR=1.16 for rs5848
(GRN) and OR=1.22 rs1990622 (TMEM106B), with the risk alleles as previously
described.  Sulfonylureas, a widely-prescribed drug class used to treat diabetes, also
modify human ABCC9 protein function.  A subsample of patients from the NACC
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database (n=624) were identified who were older than age 85 at death with known
drug history.  Controlling for important confounders such as diabetes itself, exposure to
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we describe a novel and targetable dementia risk factor.
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Abstract 
 
Hippocampal sclerosis of aging (HS-Aging) is a high-morbidity brain disease in the elderly but risk 
factors are largely unknown.  We report the first genome-wide association study (GWAS) with HS-Aging 
pathology as endophenotype.  In collaboration with the Alzheimer’s Disease Genetics Consortium, data 
were analyzed from large autopsy cohorts: (#1) National Alzheimer’s Coordinating Center (NACC); (#2) 
Rush University Religious Orders Study and Memory and Aging Project; (#3) Group Health Research 
Institute Adult Changes in Thought study; (#4) University of California at Irvine 90+ Study; and (#5) 
University of Kentucky Alzheimer’s Disease Center.  Altogether, 363 HS-Aging cases and 2,303 
controls, all pathologically confirmed, provided statistical power to test for risk alleles with large effect 
size.  A two-tier study design included GWAS from cohorts #1-3 (Stage I) to identify promising SNP 
candidates, followed by focused evaluation of particular SNPs in cohorts #4-5 (Stage II).  Polymorphism 
in the ATP-binding cassette, sub-family C member 9 (ABCC9) gene, also known as sulfonylurea receptor 
2 (SUR2), was associated with HS-Aging pathology.  In the meta-analyzed Stage I GWAS, ABCC9 
polymorphisms yielded the lowest p-values, and, factoring in the Stage II results, the meta-analyzed risk 
SNP (rs704178:G) attained genome-wide statistical significance (p=1.4x10
-9
), with odds ratio (OR) of 
2.13 (recessive mode of inheritance).  For SNPs previously linked to hippocampal sclerosis, meta-
analyses of Stage I results show OR=1.16 for rs5848 (GRN) and OR=1.22 rs1990622 (TMEM106B), with 
the risk alleles as previously described.  Sulfonylureas, a widely-prescribed drug class used to treat 
diabetes, also modify human ABCC9 protein function.  A subsample of patients from the NACC database 
(n=624) were identified who were older than age 85 at death with known drug history.  Controlling for 
important confounders such as diabetes itself, exposure to a sulfonylurea drug was associated with risk for 
HS-Aging pathology (p=0.03).  Thus we describe a novel and targetable dementia risk factor.  
 
KEYWORDS (6): 
Oldest-old, neuropathology, KATP, CTAGE5, ADGC, potassium channel 
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Introduction 
In elderly individuals, hippocampal sclerosis of aging (HS-Aging) is a relatively common brain disease 
[50,41]; for recent reviews, see Refs [51,80].  HS-Aging is defined by pathological manifestations: neuron 
loss, gliosis, and atrophy in the hippocampal formation, not deemed attributable to Alzheimer disease 
(AD)-type plaques and tangles [44,51,1].  The presence of HS-Aging pathology is associated with 
substantial cognitive impairment, independent of comorbid pathologies [48], yet this disease is generally 
misdiagnosed as AD in the clinical setting [57,9]. 
Genetic risk factors of HS-Aging are not fully characterized.   Hippocampal sclerosis pathology 
in AD cases has been linked to single nucleotide polymorphisms (SNPs) at genomic loci previously 
associated with frontotemporal lobar degeneration (FTLD), namely rs5848 (GRN) and rs1990622 (near 
TMEM106B) [63,17,76].  In contrast to AD, the risk of developing HS-Aging pathology is not associated 
with apolipoprotein E (APOE) alleles [41,50,9,72].   
There has been no prior published genome-wide association study (GWAS) focused on HS-Aging 
pathology.  The endophenotype is deceptively complex [51,80], and confers both potential obstacles and 
opportunities for a GWAS.  Challenges include the requirement for reliable autopsy data on every 
research subject, and the advanced old age of many patients with HS-Aging [50,79].  Even archival 
neuropathology data must be interpreted with caution because HS-Aging has only recently been the 
subject of widespread attention by researchers [9,51,62,57].  After accounting for these difficulties, there 
are characteristics of HS-Aging pathology that are conducive for GWAS.  Most important is the high 
disease prevalence which enables analyses of diverse study cohorts including population-based samples 
[80,41,51].  HS-Aging pathology tends to co-occur with hippocampal TAR DNA binding protein 43 
(TDP-43) pathology [2,54,36], an important component of the pathological endophenotype [51].  Thus a 
successful HS-Aging GWAS study would detect allele(s) associated with hippocampal sclerosis and 
TDP-43 pathologies across multiple cohorts of autopsied elderly individuals.   
For the current study, genomic and pathologic data from dozens of different research centers were 
analyzed with the goal of identifying alleles associated with risk for HS-Aging pathology.  Altogether 
these analyses incorporated 363 HS-Aging cases and 2,303 controls with neuropathologic evaluation.  A 
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two-tiered study design employed a GWAS to identify promising risk allele candidates, with subsequent 
evaluation of specific candidate alleles using separate cohorts.  Our main findings are: 1) a polymorphism 
in the ATP-binding cassette, sub-family C member 9 (ABCC9) gene, also known as sulfonylurea receptor 
2 (SUR2), is associated with HS-Aging pathology, and 2) exposure to sulfonylurea drugs is associated 
with increased risk for HS-Aging pathology among individuals who died age 85 and older. 
 
Materials and Methods 
Datasets  
The Alzheimer’s Disease Genetics Consortium (ADGC) accrued genomics data from 34 different 
research centers (U.S. National Institute on Aging Alzheimer’s Disease Centers, or ADCs) with multiple 
iterations of GWAS data (Refs [47,29,39] and see below), which were analyzed with neuropathological 
and clinical data obtained through the National Alzheimer’s Coordinating Center (NACC; see Ref. [4]).  
Research using NACC data was approved by the University of Washington Human Subjects Division; 
other protocols were supervised by local Institutional Review Boards.  Neuropathologic evaluations were 
performed according to center-specific protocols -- including whether neuropathologists studied left, 
right, or bilateral hippocampi [9] -- and entered into a database in standardized format.  Details of HS-
Aging case/control operationalization have been discussed before [9] and are described in detail in 
Supplemental Methods.  University of Kentucky submits data to NACC, but data from that center were 
excluded from the Stage I cohorts.  In addition to the ADGC/NACC group, autopsy series included in the 
Stage I phase were the Rush University Religious Orders Study and Memory and Aging Project (ROS-
MAP) with recruitment in Chicago, IL, USA [7], and the Adult Changes in Thought (ACT) study from 
the Group Health Cooperative and University of Washington with recruitment in Seattle, WA, USA [45].   
Following the GWAS on Stage I datasets, additional studies were performed analyzing data from 
two separate cohorts (Stage II): the University of Kentucky Alzheimer’s Disease Center (UK-ADC; 
included in this cohort were research subjects [n=49] from the Georgia Centenarian Study [59] that were 
evaluated neuropathologically at the University of Kentucky [50]), and the University of California at 
Irvine 90+ Study (UCI90+).  UCI90+ is a population-based longitudinal study of individuals aged 90 and 
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older, with recruitment in Orange County, CA, USA; there is no overlap with the ADGC/NACC data.  
Descriptions of these autopsy cohorts were published previously [65,50,15,3].  Immunohistochemical 
stains on hippocampal formation were performed using phosphorylated TDP-43 (P-TDP43) antibody 1D3 
[53] as described previously [51].  The reason for using P-TDP43 immunostaining-based endophenotype 
for UK-ADC and not UCI90+ relates to a lack of analogous P-TDP43 immunohistochemical data. 
For assessment of the prevalence of HS-Aging pathology in a population-based cohort, relative to 
other neuropathologically defined diseases, the Nun Study data [46,74] were analyzed (n=436 research 
subjects).  These data were separate from the genomics analyses.  Nun study neuropathologic methods 
were as previously described [50].  For the present study, neuropathologic observations were graded 
independently of each other: HS-Aging pathology [44,51], AD pathology (stratified by Braak stages [8] 
using both a stringent criterion [stages V/VI] and another that also incorporates milder cases [stages IV-
VI]), neocortical Lewy body pathology of a severity to indicate “high likelihood” that “the pathologic 
findings are associated with a DLB clinical syndrome” [43], and FTLD [42]. 
 
Statistical Methods 
In silico studies were performed for feasibility and power analyses.  With the sample size of the Stage I 
cohorts (241 cases, 1,998 controls), the probability of determining a “true-positive” SNP associated with 
HS-Aging pathology, i.e. statistical power, was calculated.  QUANTO software v.1.2.4 [25] was used to 
model the impact on statistical power of varying minor allele frequency (MAF) and the effect size of the 
risk allele.  That effect size is operationalized by the odds ratio (OR) of HS-Aging pathology in risk SNP 
carriers versus non-carriers.  Analyses were performed for an experiment that would meet criteria for 
genome-wide significance, pre-specified at p<5x10
-8
 [11,39].   This threshold corrects for multiple 
comparisons while also assuming that many SNPs are in linkage disequilibrium with each other and thus 
are not truly independent tests [28,20].  A second model was performed relaxing the criteria for genome-
wide statistical significance to p<10
-5
 to reflect the requirement of a risk allele candidate that could be 
tested separately in Stage II cohorts. 
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Stage I (GWAS) and Stage II (Focused on individual SNP) studies 
GWAS data access was coordinated through ADGC, providing quality-controlled genotypes using 
imputation to the Phase I v.3 1000 Genomes Project March 2012 release with imputation as previously 
described [39].  Additional quality control (QC) was applied within each Stage I dataset.  To reduce the 
potential biases associated with population stratification, principal components (PCs) were iteratively 
calculated with normalized SNP data, and subjects with outlying values were removed after each of six 
iterations using SVS™ software.  An additive mode of inheritance (MOI) was assumed in each cohort 
from the Stage I stage to balance statistical power with concerns of multiple testing, and logistic 
regression was performed for each SNP with correction for PCs.  The number of PCs chosen for 
adjustment was based on examination of scree plots (Supplemental Fig. 1) for each Stage I cohort: four 
PCs for NACC and ROS-MAP; three PCs for ACT. For assessment of rs5848 and rs1990622 SNPs, for 
which prior published studies derived from Mayo Clinic data [63,57,61], a dataset lacking that 
institution’s participants was used for analyses of those alleles.   Results across the three Stage I datasets 
were meta-analyzed using an inverse-variance-based statistic [70].  LocusZoom plots [60] reflect regional 
meta-analyzed p-values from all the Stage I datasets.  
In the Stage II cohorts, SNPs were characterized using Life Technologies’ TaqMan-based SNP 
assays providing direct assessment of genotype.  All tests for genotype/HS-Aging association were two-
tailed.  Meta-analyses were performed for the two Stage II cohorts, and then data were combined across 
all Stage I and Stage II cohorts, using an inverse-variance-based statistic as above.  Forest plots displaying 
cohort-specific and aggregated ORs and confidence intervals were created reflecting these meta-analyzed 
results using R v.3.0.2 programming language [71].   
 
Genomic ABCC9 sequencing from HS-Aging cases and controls 
Gene-specific genomic sequencing was performed on DNA from six individuals with pathologic and 
genomic information (three rs704178 G/G HS-Aging cases, three elderly rs704178 C/C controls).  Data 
pertaining to all six individuals are provided in Supplemental Methods, as are details of the sequencing 
protocol.  Briefly, ABCC9 sequences were captured using the HaloPlex Target Enrichment System 
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(Agilent Technologies) to amplify fragments spanning the human genomic region chr12:21950273-
22094386 (GRCh37/hg19 genomic assembly).  The six resulting fragment libraries were run in a single 
flow cell on a HiSeq 2500 (Illumina).  The variant files were inspected both manually and with custom 
Perl scripts. 
 
Western blots on hippocampal proteins from HS-Aging cases and controls  
Sequential biochemical fractionation and immunoblot studies employed techniques modified from previous 
protocols [64,54,51] as described in detail in Supplemental Methods.  Briefly, hippocampal tissue (CA1 and 
subiculum) was dissected from a convenience sample of postmortem brain specimens (n=9) including subjects 
with or without the ABCC9 polymorphism, and with or without HS-Aging pathology, which were extracted 
into separate low salt-, 1% Triton-X100-, 1% Sarkosyl+heat-, and 7M urea-extractable fractions.  Equal 
amounts of protein were loaded to a denaturing SDS polyacrylamide gel prior to immunoblot analyses.  
Antibodies used for immunoblots were as follows: anti-SUR2B (C-15): sc-5793; anti-SUR2A (T-19): sc-
32461; and anti-SUR2 (H-80): sc-25684, all three from Santa Cruz Biotechnology, and anti-SUR2B 
(N323A/31) and anti-SUR2A (N319A/14) from EMD Millipore.  Control immunoblots using the same 
samples were performed using anti-PGRN/GRN (R&D Cat # AF 2420), and anti--Actin (Rockland Code 
600-401-886) antibodies; see Supplemental Methods. 
 
NACC neuropathology and drug data 
The initial data source for these analyses were research volunteers evaluated after 2009 at an ADC with both 
reported clinical (including drug information) and autopsy data.  Participants were excluded if they were 
younger than 85 at death to best match all participants to HS-Aging age range.  Methods and rationale for the 
UDS clinical examination have been previously published [4,5].  All participants received an initial in-person 
clinical evaluation and up to seven follow-up evaluations; data were collected on an approximately annual 
basis.  In this analysis, HS-Aging pathology was defined as present if the neuropathologist recorded a “primary 
or contributing pathologic diagnosis of hippocampal sclerosis” among participants who died at age 70 years or 
older.  Assessment of TDP-43 pathology was not collected on the NACC Neuropathology form, but allowed as 
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a write-in; for individuals without FTLD, where some sort of medial temporal lobe TDP-43 pathology was 
noted, these cases were considered to be HS-Aging (n=4).  
For statistical analyses of the NACC data, longitudinal self-reported medication histories were 
reviewed for the 624 included subjects.  Medication use was determined by asking subjects to provide a list of 
all medications taken within the last two weeks prior to their UDS assessment.  Individuals who reported 
taking any sulfonylurea at any time during follow-up (September 2005 through April 2013) were coded as 
positive for use.  Crude and adjusted ORs for presence of HS-Aging at autopsy were calculated separately.  
Adjusted ORs were obtained via logistic regression, controlling for age at death (centered at 90) and year of 
death (centered at 2011).  Possible group differences in mean age at death and interval between last evaluation 
and death were assessed using linear regression.  Sensitivity analyses were conducted restricting the 
medication history to the last UDS assessment.  Analyses were conducted using SAS/STAT 9.3®.  Two-tailed 
tests were used to evaluate the hypothesis that use of sulfonylureas promotes HS-Aging pathology (α=0.05).   
 
Results 
Endophenotype for GWAS and subsequent studies 
The endophenotype used for correlation with genomic information was HS-Aging pathology [51,9].  
Photomicrographs (Fig.1) demonstrate features of HS-Aging pathology discernible after staining human 
hippocampal sections with hematoxylin and eosin (H&E) and using P-TDP-43 immunohistochemistry.  A 
three-tier (0-2) semiquantitative scale of P-TDP-43 immunoreactive pathology was used in the UK-ADC 
dataset.  Data about the prevalence of HS-Aging pathology, from the Nun Study, are shown in Fig. 2.  
Nun Study research volunteers were followed as a population-based cohort, mostly from normal status, 
and with high autopsy rate [46,74]; this group lacked some of the recruitment biases of dementia clinic 
cohorts [46,50,6,35].  Even when younger Nun Study research volunteers were included from the sample 
studied neuropathologically at University of Kentucky (total n=526), no FTLD-TDP cases were observed 
(data not shown).  By contrast, HS-Aging pathology is relatively prevalent in population-based cohorts, 
which are key sources of data in the current study (ROS-MAP, ACT, and UCI90+ studies).   
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Statistical and feasibility considerations  
GWAS in Stage I cohorts was used to identify risk SNP candidates, followed by separate analyses of 
individual SNPs in Stage II cohorts (Fig. 3).  This study design involved three key assumptions:  
Assumption #1 (central hypothesis being tested in the study)>    As there has been no prior published HS-
Aging GWAS, polymorphisms remain to be described with strongly increased odds of HS-Aging 
pathology in risk allele carriers versus non-carriers, i.e. OR>1.5 for the risk allele; 
Assumption #2>    The Stage I cohort GWAS comprises adequate sample sizes to yield a limited number 
of credible candidate risk SNPs for evaluation in the Stage II cohorts; and 
Assumption #3>    The Stage II cohorts have sufficient numbers of HS-Aging cases and controls to 
adequately test for an HS-Aging risk SNP candidate.   
Power analyses were performed to test whether Assumptions #2 and #3 were valid if the large effect 
size SNP (Assumption #1) exists.  The effect size strongly influences statistical considerations (Fig. 4).   
Given sample sizes, the likelihood of uncovering an HS-Aging risk allele with genome-wide statistical 
significance (p<5x10
-8
) in the Stage I GWAS was only modest, unless the effect size was quite large (Fig. 
4a).  However, the Stage I cohort was adequately powered for the purposes of identifying risk SNP 
candidates for downstream evaluation.  In the presence of a strong HS-Aging risk allele (OR>1.5), there 
was a high chance that the risk allele would be identified in the Stage I cohort GWAS with p<10
-5
 (Fig. 
4b).  Definitive testing of the candidate risk SNPs would require downstream validation in independent 
cohorts.  Stage II would be most effective in the case of a SNP with high MAF, and with studies of 
individual SNPs performed serially so that the final cohort’s analyses require no adjustment for multiple 
comparisons. 
 
GWAS 
As a positive control, a GWAS from AD pathology was performed initially on a sample from the ADGC 
cohort (1,443 AD cases and 99 controls), and, as expected, only SNPs near the APOE gene reached 
genome-wide significance (p=4.2x10
-13
; Supplemental Tables 1,2, Supplemental Fig. 2).  We then 
performed a HS-Aging GWAS using data from the three Stage I datasets: ADGC/NACC, ROS-MAP, and 
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ACT (Table 1 and Supplemental Table 3).  The number of nominal SNPs that passed QC and were 
included in the GWAS was ~4.9 million (Table 2).  HS-Aging cases and controls were classified 
according to pathology irrespective of AD or other prevalent pathologies; see Supplemental Methods for 
details.  Manhattan plot and Q-Q plot for the HS-Aging GWAS are shown in Fig. 5; no Stage II cohort 
data were factored into these analyses. 
The GWAS included individual SNPs previously linked to HS-type pathology [57], specifically, 
rs5848 [61] and rs1990622 [63].  For analyses of these alleles, a separate GWAS was performed using 
Stage I cohort cases and controls that did not overlap with prior studies of rs5848 and rs1990622.  The 
SNPs previously linked to HS-Aging pathology can be tested with less stringent p-value cutoffs due to 
targeted testing (α=0.05; two-tailed tests are reported without adjustment for the performance of two 
tests).  Results are shown in Table 3 and Fig. 6.  Meta-analyses of Stage I cohorts results show OR=1.16 
(95% CI 0.92-1.46) for rs5848, OR=1.22 (95% CI 1.00-1.49) for rs1990622, with all cohorts tested 
demonstrating the same risk alleles (T allele for both SNPs) as previously described [63,61]. 
GWAS from meta-analyzed Stage I datasets detected no SNP associated with HS-Aging 
pathology so strongly as to achieve genome-wide statistical significance.  The genomic locus bearing 
SNPs with the lowest p-values in the GWAS data were in the ABCC9 gene on chromosome 12p.  The 
individual SNP that yielded the lowest p-value in the GWAS itself was rs7966849 (p=1.0x10
-7
, 
uncorrected, see Supplemental Fig. 3) in an intron of ABCC9.  SNPs from only nine different genomic 
regions showed p<10
-5
 in the GWAS (Table 4, Supplemental Table 4), including ABCC9 (15 nominal 
SNPs) and SNPs in and near CTAGE5/FBOXO33 on chromosome 14 (50 nominal SNPs; Supplemental 
Fig. 4).   
 
Stage II analyses 
The initial criteria for deciding which candidate HS-Aging risk alleles to test in the Stage II cohorts were 
that the same alleles would yield p<0.05 in all three Stage I cohorts.  This led us to consider ABCC9 
putative risk SNPs including rs704178, a SNP with MAF ~0.45, in strong linkage disequilibrium with 
rs7966849 (R
2
=.97 and D’=1.0) [23].  Genotype frequencies for rs704178 in HS-Aging cases and controls 
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are displayed in Table 5.  After accumulation of additional data, the rs704178 allele became the study’s 
focal-point (Figs.7-9).  Primary data from ABCC9 risk SNP rs704178 for HS-Aging cases and controls 
from the Stage II cohorts are presented in Table 6.   
The UK-ADC was the first-stage Stage II cohort for evaluating HS-Aging candidate risk SNPs.  
For this cohort, the primary criterion for a positive “case” status was aberrant P-TDP-43 
immunoreactivity in the hippocampus and subiculum, which we hypothesize provides (in the context of 
elderly individuals without FTLD) a sensitive and specific readout of HS-Aging pathology [51,2].  From 
this convenience sample of 227 patients, 82 (36.1%) were positive for P-TDP43 pathology.  Ten initial 
SNP risk allele candidates from the Stage I datasets were evaluated in the UK-ADC cohort: rs7206273, 
rs1538842, rs4869959, rs5848, rs201825, rs2274567, rs6656401, rs2287910, rs4144545, rs704179, and 
rs704178.  Of these, rs704178 was the only SNP showing positive association with the pathologic 
endophenotype.   
Data from the UCI90+ study [15,16], a population-based sample of 144 controls and 28 HS-
Aging cases, was the second Stage II cohort.  Here, H&E-based observation of hippocampal sclerosis 
pathology was used as the readout, since not all the cases were stained with the same P-TDP43 methods.  
The risk alleles (rs704178:G), trended toward positive association with HS pathology; no other SNP was 
tested in this dataset except rs704180, which was in complete linkage disequilibrium with rs704178 as 
expected (not shown).  This trend was only statistically significant if the recessive MOI model was 
applied (p<0.03 using two-tailed test); however, the effect size was still large at OR=1.43 (95% CI 0.80-
2.6) even with additive MOI model and two-tailed test.    
Combined meta-analyses of all Stage I and Stage II cohorts yielded a p-value of 2.4x10
-8 
with an 
additive MOI model, and p-value of 1.4x10
-9
 with recessive MOI (Fig. 8).  Dominant MOI model had far 
weaker association as is shown in Supplemental Fig. 5.  Having found the same ABCC9 gene 
polymorphism is associated with hippocampal P-TDP43 pathology or HS-Aging pathology in two Stage 
II cohorts in addition to HS-Aging pathology in the Stage I cohorts, we focused on ABCC9 in subsequent 
studies.   
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Post-hoc studies related to ABCC9 
To assess preliminarily whether the ABCC9 risk alleles are proxies for as-yet uncharacterized genomic 
feature(s), ABCC9 gene-specific sequencing was performed using genomic DNA (Supplemental 
Methods).  For these studies, DNA was isolated from hippocampi of three autopsy-confirmed HS-Aging 
cases homozygous for ABCC9 risk SNPs (rs704178: G/G) and the results were compared to three 
individuals over 95 at death (rs704178: C/C) and lacking HS-Aging pathology (Supplemental Methods).  
No previously uncharacterized genomic feature (including exonic SNP) was discovered for which the 
SNPs would be a proxy.  As expected, SNPs in known linkage disequilibrium with the rs704178 SNP 
span a region over 10 exons (Fig. 9). 
Western blots were performed on protein samples from snap-frozen human hippocampi to 
address whether differences in ABCC9 polypeptides can be observed in correlation with particular HS-
Aging risk alleles or pathologic status.  These experiments were designed to test for a qualitative change 
in ABCC9 protein such as insoluble aggregates, proteolytic fragments, or complete loss of expression.  
The convenience subsample from the UK-ADC comprised nine human hippocampi including HS-Aging 
and controls, and different homozygous ABCC9 genotypes.  Different protein extraction methods were 
utilized and five different commercially available anti-ABCC9 antibodies were applied.  These 
experiments discovered no evidence of a specific qualitative change in hippocampal ABCC9 protein 
products, with caveats related to the small number of cases evaluated, and to the inconsistency in the 
protein blotting characteristics observed for these antibodies (Supplemental Fig. 6).  The imperfect 
antigenic specificity for the five putative ABCC9 antibodies also rendered immunohistochemistry 
technically unsatisfactory, although this was attempted (not shown).   
The ABCC9 gene is also known as sulfonylurea receptor 2, SUR2.  Sulfonylureas are a widely 
prescribed class of drugs used to treat type II diabetes mellitus; these drugs antagonize the function of the 
ABCC9 protein product [10,68,33,13].  We tested the hypothesis that exposure to sulfonylurea drugs is 
associated with altered risk for HS-Aging pathology (Table 7).  Data were obtained from NACC database 
with both longitudinal drug history and postmortem data from individuals dying age 85 and above with 
autopsies between 2010 and 2013.  HS-Aging pathology was observed in 17.3% (108/624) of all 
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autopsied cases in the sample, 30.6% of sulfonylurea users and 16.5% of non-users.  Based on a two-
tailed test and alpha=0.05, the crude OR for autopsy-confirmed HS-Aging pathology after use of any 
sulfonylurea versus no sulfonylurea use was 2.23 (95% CI: 1.06–4.68, p=0.03; age-adjusted OR=2.19 
(95% CI: 1.04–4.63, p=0.04)).  Use of any sulfonylurea was reported by 11 HS-Aging and 25 non HS-
Aging subjects. When the analysis was restricted to the medication history given at the last assessment 
before death, the crude OR for use of any sulfonylurea was 2.52 (95% CI: 1.10–5.76, p=0.02; age-
adjusted OR=2.49 (95% CI: 1.08–5.75, p=0.03)).  There was neither positive nor negative association 
between sulfonylurea use and AD pathology, operationalized as AD-positive if Braak stage V or VI and 
AD-negative otherwise (not shown).  These data are compatible with the hypothesis that sulfonylurea 
exposure is associated with HS-Aging pathology in this sample.   
Potential confounders include the clinical indication for sulfonylurea use, namely type II diabetes.  
Of subjects who reported taking any anti-diabetic agent (62/624), most reported use of a sulfonylurea 
(36/62).  The association with HS-Aging pathology was not dependent upon diabetes itself because, in the 
NACC database overall, history of diabetes had a null association with HS-Aging pathology [52].  In this 
subsample, the odds of observing HS-Aging pathology were not increased for anti-diabetic agent users as 
a whole (age-adjusted OR=1.43 (95% CI: 0.75–2.71, p=0.28)), for anti-diabetic agent users who never 
reported using a sulfonylurea (age-adjusted OR=0.60 (95% CI: 0.17–2.04, p=0.41)), or for self-reported 
diabetes (age-adjusted OR=1.08 (95% CI: 0.58-2.03, p=0.81)).   
For a slightly younger group of research subjects, those dying age 80-84 (n=261), among whom 
HS-Aging histopathology was relatively uncommon [9], post-hoc sensitivity analyses indicated no 
association between sulfonylurea use and HS-Aging pathology (age-adjusted OR=0.59 (95% CI: 0.13-
2.68)).  Effect estimates in this group are similar for use of any anti-diabetic medication (age-adjusted 
OR=0.33 (95% CI: 0.07-1.42)) and self-reported diabetes (age-adjusted OR=0.43 (95% CI: 0.15-1.29)).  
Results in this slightly younger group of subjects, which included only 17 sulfonylurea users, did not 
support the hypothesis that sulfonylurea use is associated with HS-Aging pathology in this age group.  
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Discussion 
In the large human autopsy cohorts studied, the risk of developing HS-Aging pathology was associated 
with polymorphism in the ABCC9 gene.  The effect size was relatively large (OR=1.4-2.0 with additive 
MOI, 2.0-2.7 with recessive MOI) in all three Stage I cohorts and also in both Stage II cohorts.  In the 
final Stage II cohort, only a single polymorphism was queried so statistical correction for multiple testing 
was obviated.  The HS-Aging risk allele may be directly relevant to public health because aged human 
subjects in the NACC database with history of sulfonylurea exposure have increased risk for HS-Aging 
pathology.   
There are potential pitfalls inherent to the study design.  The Stage I GWAS did not produce a 
SNP that reached genome-wide statistical significance.  Bias was thus inserted into the study by our 
selecting which SNPs would be analyzed in the Stage II cohorts.  Among the candidate SNPs from 
GWAS, ABCC9 polymorphisms ultimately yielded the lowest p-values by an order of magnitude, so that 
locus was an obvious choice to evaluate.  Testing the association between sulfonylurea drug exposure and 
HS-Aging pathology in the NACC dataset is complicated by confounders and limitations.  For example, 
the accuracy of medication self-report is imperfect since current medication use refers to the two-week 
period prior to the clinical assessment, drug dosages were unknown, and some of the patients presumably 
used and discontinued sulfonylurea drugs prior to study enrollment as well as between annual study 
visits.  Patient age was also a relevant factor; we found that HS-Aging pathology is relatively unusual 
among individuals younger than age 85 [51,9,50,49] and found no evidence for correlation between the 
sulfonylurea drugs and HS-Aging pathologically in the post-hoc analysis of younger patients.  These 
analyses were also performed blind to patients' genotypes so the distribution of ABCC9 SNPs versus 
sulfonylurea use is unknown.  For these reasons, the data on HS-Aging linked to drug exposure should be 
interpreted with caution. 
The present study was not designed to evaluate polymorphisms that show weak associations with 
HS-Aging pathology.  There were, however, some alleles from the GWAS that appear interesting despite 
failing to reach genome-wide statistical significance.  For example, SNPs within and near the cutaneous 
T-cell lymphoma-associated antigen 5 (CTAGE5) gene yielded p~10
-6
 in the GWAS, and CTAGE5 
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polymorphisms have been linked to familial idiopathic basal ganglia calcification (Fahr's disease) [40,56].  
Meta-analyses of Stage I cohort data also indicated that alleles linked previously to hippocampal sclerosis 
pathology -- rs5848 [17] and rs1990662 SNPs [63]  -- trend toward association with HS-Aging pathology 
as operationalized in the current study, with the same risk alleles as previously described [61,63,57], and 
with OR~1.2 (meta-analyzed data, additive MOI).   
The main discovery of the present study is the association between HS-Aging pathology and 
polymorphism in the ABCC9 gene.  Meta-analyzed data indicate an overall OR=1.62 with the additive 
MOI model – a relatively large effect size for a common allele [24,81,11].  Notably, the chromosomal 
region in which ABCC9 resides (12p) has been linked to clinical late-onset AD risk [31,66], which may 
be at least partially explained by ABCC9, because HS-Aging tends to be misdiagnosed clinically as AD 
[57,9].   
We can begin to develop hypotheses about mechanism(s) underlying the genomic associations.  
The presence of hippocampal TDP-43 pathology is associated with additive cognitive impairment [37,48], 
and “unilateral” HS-Aging pathology usually shows TDP-43 pathology on the contralateral side [50]; the 
present study affirms that hippocampal TDP-43 pathology is linked to HS-Aging pathology, since risk for 
both is associated with the same allele, rs704178.  The strength of the association between rs704178 and 
HS-Aging pathology with recessive model of MOI (OR=2.13) indicates that the “non-risk alleles” may 
exert an adaptive function, even in the heterozygous state (“dominant” gain-of-function pattern).   
The association between ABCC9 and HS-Aging provides a novel insight into neurodegenerative 
diseases.  Prior GWAS found that different polymorphisms of the ABCC9 gene were associated with 
cardiac problems and altered sleep patterns [58,55,32,34,38], which could theoretically be pathogenetic 
factors “upstream” from HS-Aging.  Alternatively, or in addition, ABCC9 polymorphisms may exert 
influence through blood vessel pathology.  The ABCC9 polypeptide product (SUR2) is physiologically 
active in arteriolar smooth muscle [55,22], and pathologically-confirmed arteriolosclerosis is relatively 
severe in brains that also harbor HS-Aging pathology [52] (and see Ref [18]).  Stop codon mutations in 
ABCC9 lead to Cantú syndrome [75,26], a rare condition with mostly uncharacterized neuropathology.  
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Intriguingly, Cantú syndrome patients have demonstrated vascular anomalies, including in the brain 
[27,21,67].    
What about the function of the HS-Aging risk SNPs themselves?  These intronic SNPs span at 
least ten ABCC9 exons.  Some mRNA variants have been described with splice junctions near the HS-
Aging risk SNPs [78,12].   In the Genotype-Tissue Expression project (GTEx) database [14] of 
expression quantitative trait loci, SNPs linked to HS-Aging pathology (particularly rs704192 which has 
D’>0.9 with rs704178) also correlate with altered ABCC9 expression specifically in both human 
hippocampus and amygdala (both p<0.05) but not cerebellum.  Using SNPExp web tool [30] where SNPs 
are correlated with gene expression using transformed lymphoblastoid cell lines, SNPs linked to HS-
Aging pathology (particularly rs829080, with D’=1.0 with rs704178) correlate strongly with ABCC9 
expression (p<0.0001).  Despite these interesting observations, it is not yet proven that the HS-Aging risk 
SNP variability leads directly to changes in gene splicing, mRNA expression, or polypeptide function in 
human brain.   
Whatever the mechanism(s), ABCC9 polymorphism in a relatively large number of human cases 
is associated with HS-Aging pathology.  The differing neuropathologic findings and differing genetic 
vulnerabilities of HS-Aging and AD make it likely that prevention and treatment of HS-Aging, when 
achieved, will be different from prevention and treatment for AD.  ABCC9 function is sensitive to 
pharmacologic manipulation, and we here report that in subjects dying after age 85, sulfonylurea drugs 
exposure was associated with HS-Aging pathology.  This study may herald progress of clinical relevance, 
because ABCC9 agonists have been described, and may be neuroprotective [82,77].  We conclude that the 
present study establishes a pathogenetic association between ABCC9 and HS-Aging pathology – and 
perhaps the basis for a novel future therapeutic strategy.   
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Figure Legends 
 
Fig. 1  Hippocampal sclerosis of aging (HS-Aging) pathology is a complex endophenotype for genomic 
studies.  Pathology defines the disease, illustrated in photomicrographs of hematoxylin and eosin-stained 
sections to compare an aged control hippocampus (a) with a shrunken HS-Aging hippocampus (b); same 
scale bar =2mm, CA1 subfield indicated.  For grading P-TDP43 pathology in CA1 and subiculum of the 
hippocampal formation, a three-tier semiquantitative system was employed with “Grade 0” indicating no P-
TDP43 pathology, “Grade 1” (c,d) indicating very sparse isolated pathology (P-TDP43 positive neuronal 
inclusion at arrow) and “Grade 2” (e,f) indicating any more severe pathology, usually with intranuclear, 
intracytoplasmic (arrow), and neuritic P-TDP-43 pathology.  Scale bar = 60 microns (c and e) and 25 
microns (d and f).   
 
 
Fig. 2 Prevalence of brain pathology subtypes in the Nun Study.  The prevalence of HS-Aging pathology is 
germane to a study that incorporates different autopsy cohort types.  Here we show data about the prevalence 
of brain pathology subtypes in the Nun Study, a population-based cohort as previously described in detail 
[50].  As in most community-based or population-based cohorts (as opposed to cohorts connected with 
memory disorder clinics), frontotemporal lobar degeneration (FTLD) pathology is rare [19,69,73]. 
 
 
Fig. 3 Study design for elucidating a large effect size human genomic polymorphism that is associated with 
HS-Aging pathology.  The GWAS (Stage I) incorporated genomic data from Alzheimer’s Disease Genetics 
Consortium (ADGC) and pathologic data from National Alzheimer’s Coordinating Center (NACC) derived 
from 34 different U.S. Alzheimer’s Disease Centers;   Rush University Religious Orders Study and Memory 
and Aging Project (ROS-MAP); and, the Group Health Research Institute Adult Changes in Thought study 
(ACT).  Subsequent evaluation of particular risk alleles was then performed (Stage II) using data from two 
additional cohorts:  University of Kentucky ADC (UK-ADC); and University of California at Irvine 90+ 
Study (UCI90+).  Post-hoc studies were performed on the ABCC9 allele (rs704178) showing the most robust 
association with HS-Aging pathology. 
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Fig. 4  Statistical power analyses.  With the sample size of the Stage I cohorts (241 cases, 1,998 controls), 
the probability of elucidating a “true-positive” SNP associated with HS-Aging pathology were modeled.  
Two different genome-wide significance thresholds were modeled, each with varying minor allele frequency 
and risk allele effect sizes operationalized by the odds ratio of HS-Aging pathology in risk SNP carriers 
versus non-carriers.  To reflect the study design, the p-values were set at p<5x10
-8
 (a) and p<10
-5
 (b). 
 
 
Fig. 5 HS-Aging GWAS using data meta-analyzed from the three Stage I cohorts.  (a) Manhattan plot 
showing p-values for HS-Aging GWAS with meta-analyzed data from the three Stage I cohorts.   No SNP 
was found to reach genome-wide statistical significance (p<5x10
-8
 to correct for multiple comparisons) in 
this GWAS. Two loci with the lowest p-values SNPs in the Stage I GWAS are highlighted in red: ABCC9 
(Chr 12p) and CTAGE5/FBXO33 (Chr 14q).  (b) QQ Plot for HS-Aging GWAS using ADGC data. 
Observed (log-transformed) p-values for each SNP are plotted against their corresponding expected 
values under the null hypothesis of no association with HS-Aging.   
 
 
Fig. 6 LocusZoom plots of HS-Aging GWAS data.  Results of HS-Aging GWAS meta-analyzed data 
from Stage I datasets are shown.  The y axis shows p-values describing the results of association study 
with HS-Aging phenotype centered on (a) GRN locus (rs5848) on Chromosome 17 and (b) TMEM106B 
locus (rs1990622) on Chromosome 7.   Note that the SNPs being evaluated have been published 
previously [63,17] and this is a sample of cases and controls that is independent from prior published 
studies of these alleles.  Since this part of our study is a replication experiment, and focused on the two 
particular alleles, p<0.05 findings would constitute a successful replication. 
 
 
Fig. 7 LocusZoom plots of HS-Aging GWAS data.  Results of HS-Aging GWAS meta-analyzed data 
from Stage I datasets are shown.  The y axis shows p-values describing the results of association study 
with HS-Aging phenotype centered on the ABCC9 rs704178 risk allele that was the subject of further 
study.  The data shown here are independent of the subsequent studies in two additional Stage II cohorts. 
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Fig. 8  The ABCC9 risk allele (rs704178) association with HS-Aging pathology.  Analyses were 
performed for each individual autopsy cohort, and then combined using meta-analyses across all six Stage 
I and Stage II cohorts, using inverse-variance based statistic [70].  Forest plots displaying cohort-specific 
and aggregated odds ratios (OR) and 95% confidence intervals (CIs) were created reflecting these meta-
analyzed results.  Lines represent 95% CIs for the ORs, and the size of the square (cohort) or trapezoid 
(meta-analyzed group) reflects the cohort size.  Shown here are the results when assuming an additive 
mode of inheritance (a) or recessive (b) model of inheritance.   
 
 
 
Fig. 9 ABCC9 gene and protein organization in relation to the HS-Aging risk alleles.  (a) There are at 
least 38 exons in the ABCC9 gene, and the SNPs that are most strongly linked to HS-Aging are present 
within a 20 kilobase region.  (b) The approximate location of the exons on the corresponding ABCC9 
polypeptide is shown with a red arrow.  TM=transmembrane; NBD=nucleotide binding domains.  (c) 
Direct genomic sequencing of the ABCC9 gene was performed for six cases (3 rs704178 G/G HS-Aging 
cases, 3 elderly controls with rs704178 C/C genotype).  Intron-by-intron analyses indicate that the 
intronic polymorphisms linked to HS-Aging pathology span more than ten exons. 
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Table 1  Research subjects (n=2,666 research subjects total) and the five autopsy cohorts 
analyzed in the current study 
 
 
Autopsy 
Cohort 
Pathologic phenotype 
evaluated 
HS 
Cases 
Avg age 
(Yrs±st dev) 
Non-HS 
Controls 
Avg age 
(Yrs±st dev) Total 
Role in 
study 
ADGC HS pathology 186 84.1±8.2 1450 81.5±8.7 1636 
Stage I 
(GWAS)  
ROS-MAP HS pathology 29 93.3±5.4 398 90.8±4.1 427 
ACT HS pathology 26 87.6±4.2 150 88.4±2.2 176 
UK-       
ADC 
Hippocampal TDP-43 
pathology 
94 92.3±6.9 161 93.3±6.4 255 Stage II #1 
UCI90+ HS pathology 28 94.1±2.3 144 92.3±4.5 172 Stage II #2 
 
Total 363 
 
2303 
 
2666 
 
 
 
 
 
 
Table 1 Legend. GWAS was performed on the three Stage I datasets, from Alzheimer’s Disease Genetics 
Consortium (ADGC, which are based mostly on dementia research clinics), Rush Religious Order Study 
and Memory and Aging Project (ROS-MAP, which is an epidemiologic cohort), and Adult Changes in 
Though (ACT, which is a community-based autopsy cohort).  First Stage II was performed at University 
of Kentucky Alzheimer’s Disease Center (UK-ADC), the second Stage II at the University of California 
Irvine 90+ Study (UCI90+).   None of the cases used in the assessment of HS-Aging overlapped between 
cohorts.  HS = Hippocampal sclerosis. 
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Table 2  Genotyping quality control (QC) for GWAS: Stage I datasets  
 
 
 Level 0 QC Level 1 QC   
Cohort 
(ADCs, 
via 
ADGC) 
Number of 
SNPs above 
imputation 
threshold 
Number of 
SNPs below 
initial call rate 
threshold 
(0.85) 
Number of 
SNPs below 
initial MAF 
threshold (0.01) 
Number of SNPs 
out of Hardy-
Weinberg 
equilibrium 
(p<1e-5) 
Number of 
SNPs post-
level 1 QC 
Number of 
subjects with 
NACC and 
ADGC data 
ADC1 36,642,556 832,579 28,964,437 75,832 6,886,357 1,484 
ADC2 36,274,850 643,766 28,678,144 36,123 6,964,483 210 
ADC3 36,552,919 540,092 28,804,571 48,516 7,222,900 529 
ADC4 36,644,873 848,668 29,326,492 119,205 6,594,201 127 
ADC5 36,644,873 893,321 29,350,835 30,593 6,581,733 103 
ADC6 36,644,873 849,334 29,616,694 24,304 6,345,693 56 
 
  Level 2 QC   
Cohort 
Union of 
SNPs passing 
Level 1 QC 
Number of 
SNPs below 
call rate 
threshold 
(0.95) 
Number of 
SNPs below 
MAF 
threshold 
(0.05) 
Number of 
SNPs out of 
Hardy-
Weinberg 
equilibrium 
(p<1e-5) 
Number of 
SNPs post-
level 2 QC 
Number of 
subjects 
ADCs 7,948,061 2,771,882 2,604,515 3,142 4,271,710 2,509 
 
Cohort 
Number of 
SNPs above 
imputation 
threshold 
Number of 
SNPs below 
call rate 
threshold 
(0.95) 
Number of 
SNPs below 
MAF 
threshold 
(0.05) 
Number of 
SNPs out of 
Hardy-
Weinberg 
equilibrium   
(p<1e-5) 
Number of 
SNPs post- 
QC 
Number of 
subjects 
ACT 35,550,922 1,831,347 30,043,290 24,473 4,407,882 176 
ROS-MAP 35,606,835 2,242,313 30,159,840 36,529 4,059,683 427 
 
 
Table 2 Legend.  Genotypes were imputed to the Phase I v.3 1000 Genomes Project March 2012 release 
by the ADGC. ADCs were imputed in six iterations (ADC 1-6).  Resulting SNPs within each dataset were 
screened for call rate, minor allele frequency (MAF) and Hardy-Weinberg equilibrium.  QC filters were 
applied in two separate stages for the ADGC dataset which comprises six subsets (ADC1-6).  Note that a 
SNP can fail more than one of the QC criteria.   Overall the number of SNPs that passed QC and were 
evaluated in the GWAS, i.e., the union of SNPs passing QC across the ADC, ACT and ROS-MAP 
cohorts, was 4,913,579. 
 
Table 3  Results from Stage I datasets for polymorphisms (rs5848 and rs1990622) linked 
previously to hippocampal sclerosis pathology in aged individuals 
 
 
 
 
Dataset 
Major 
allele  
Minor 
allele 
Odds 
Ratio 
95% 
Confidence 
Interval 
Risk 
allele 
p-
value* 
 ADGC C T 1.08 0.84-1.40 T 0.541 
rs5848 ACT C T 1.90 0.95-3.83 T 0.073 
(GRN) ROS-MAP C T 1.12 0.53-2.37 T 0.774 
 Meta-analysis results 1.16 0.92-1.46 T 0.218 
   
   
 
Dataset 
Major 
allele  
Minor 
allele  
Odds 
Ratio 
95% 
Confidence 
Interval 
Risk 
allele 
p-
value* 
rs1990622 ADGC T C 1.19 0.95-1.49 T 0.132 
(TMEM106B) ACT T C 1.24 0.63-2.44 T 0.528 
 ROS-MAP T C 1.43 0.82-2.50 T 0.198 
 Meta-analysis results 1.22 1.00-1.49 T 0.049 
  *-p-values shown here are assuming a two-tailed test 
 
Table 3 Legend.  Data from Stage I cohorts analyzed to test the hypotheses that previously reported 
SNPs are associated with hippocampal sclerosis risk in Stage I cohorts.   
  
Table 4  GWAS from Stage I cohorts with p<10
-5
: genomic loci, including the genes (if any) and 
individual SNP at each locus with the lowest p-value  
 
 
 
 *Genomic position refers to GRCh37/hg19 assembly. 
 
 
 
Table 4 Legend.  GWAS from Stage I cohorts yielded 86 different nominal SNPs with p<10
-5
.  These all 
derived from nine genomic regions or loci, which are shown here with each genomic locus represented by 
the SNP with the lowest p-value from each 
 
 
 
  
Gene/locus area  
# SNPS 
at locus 
with  
p<10
-5
 
SNP at locus 
with lowest 
p-value 
Chromosome: 
Genomic  
position*  
Minor 
Allele 
Major 
Allele 
MAF 
Cases 
MAF 
Controls 
p-value 
(Additive 
MOI) 
ABCC9 15 rs7966849 12: 22004199 G A 0.38 0.51 1.01E-07 
CTAGE5/FBXO33 50 rs8018486 14: 39818617 G A 0.11 0.21 1.15E-06 
Intergenic 1 rs114816986 3: 155035752 A G 0.30 0.08 1.97E-06 
Intergenic 1 rs62324179 4: 127661386 T C 0.26 0.18 3.65E-06 
Intergenic 3 rs80155385 13: 59845469 C G 0.22 0.05 4.95E-06 
Intergenic 2 rs3018573 11: 98516757 G A 0.52 0.41 6.81E-06 
FRMD4A 1 rs72769570 10: 13810428 A G 0.19 0.05 8.09E-06 
WWOX 1 rs55751884 16: 78231495 C T 0.26 0.12 9.19E-06 
Intergenic  12 rs12514988 5: 123179750 T C 0.16 0.04 9.48E-06 
Table 5  Genotype frequencies by HS-Aging status from Stage I cohorts  
 
 
rs704178 genotypes 
HS-Aging CC GC GG 
Cases 0.164 0.441 0.395 
Controls 0.259 0.500 0.242 
Total 0.249 0.493 0.258 
 
 
Table 5 Legend.  The three Stage I cohorts (ADGC/NACC, ROS-MAP, and ACT) are aggregated to 
compute genotype frequencies for the ABCC9 putative risk SNP, rs704178.   
  
Table 6  Number of research subjects in each Stage II cohort arranged by ABCC9 genotype 
status (risk allele is G) and neuropathology (P-TDP-43 or hippocampal sclerosis [HS])  
 
  
rs704178 genotypes 
Cohort Neuropathology CC GC GG 
UK-ADC 0* 35 75 35 
  1* 7 11 7 
  2* 8 24 25 
UCI90+ HS- 34 76 34 
  HS+ 7 9 12 
 
*-In the UK-ADC and UP-ADC, severity of aberrant P-TDP-43 (0-2 scale) was the pathologic readout 
 
 
Table 6 Legend.  Stage II cohorts used autopsy series independent of the Stage I datasets, with phospho-
TDP-43 (P-TDP43) pathology in the UK-ADC as the endophenotype.  Different strategies and models 
could be applied for statistical testing; for results of statistical analyses, see Fig. 8 and Supplemental Fig. 5. 
  
Table 7  Sulfonylurea use and HS-Aging risk in persons age 85 years and older at death: data 
from the National Alzheimer’s Coordinating Center (NACC) database 
 
 Sulfonylurea Use  
(N=36) 
No Sulfonylurea Use 
(N=588) 
HS-Aging 
Pathology 
(n=11) 
No HS-Aging 
Pathology 
(n=25) 
HS-Aging 
Pathology  
(n=97) 
No HS-Aging 
Pathology 
(n=491) 
Age at death, years 88.7±4.8 90.8±4.3 91.2±4.3 90.9±4.4 
Number of  
longitudinal 
evaluations 
4.5±1.1 4.4±1.7 3.9±1.8 3.9±1.7 
Last evaluation to 
death, months 
13.8±10.0 15.3±15.3 18.6±19.7 15.1±15.1 
Estimated 
sulfonylurea exposure, 
years  
3.4  
(Range 0.5-6.2) 
3.5  
(Range 0.5-6.8) 
N/A N/A 
Taking sulfonylurea at 
last evaluation, % 
81.8% 72.0% N/A N/A 
 
Table 7 Legend.  Summary statistics for data used to test of the hypothesis that sulfonylurea use is 
correlated with increased risk for HS-Aging pathology in the NACC database.  Results presented are 
mean ± SD unless otherwise stated. These analyses involved 624 patients who died after age 85, between 
2010-2013, with detailed longitudinal drug history and autopsy data.  “Sulfonylurea use” indicated self-
reported use of any sulfonylurea drug at any longitudinal visit.  Crude OR for use of any sulfonylurea was 
2.23 (95% CI: 1.06–4.68, p=0.03; age-adjusted OR=2.19 (95% CI: 1.04–4.63, p=0.04. Mean age at death 
was not different for subjects stratified by presence of HS-Aging and use of any sulfonylurea 
(F3,620=1.10,p=0.35) nor was mean time between last evaluation and date of death (F3,620=1.33,p=0.26). 
The average estimated drug exposure and % of patients taking a sulfonylurea at last visit was not different 
in persons with and without eventual HS-Aging pathology.  N/A=not applicable. 
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